Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Temuterkib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 known ✓ | P28482 | 17/20 | 1.00 |
| ▸ | MAPK3 known ✓ | P27361 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | BCR | P11274 | 1/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MAPK6 | Q16659 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837306 | 0.97 | MAPK1 (0.94) | MAPK1MAPK3ABL1BCRMAP3K14 | |
| Temuterkib SCHEMBL28928408 | 0.95 | MAPK1 (0.91) | MAPK1MAPK3ABL1BCRMAP3K14 | |
| SCHEMBL17837212 | 0.93 | MAPK1 (0.86) | MAPK1MAPK3MAP3K14MAPK6 | |
| SCHEMBL17837242 | 0.92 | MAPK1 (0.85) | MAPK1MAPK3ABL1BCRMKNK1 | |
| Temuterkib SCHEMBL28654935 | 0.91 | MAPK1 (0.83) | MAPK1MAPK3ABL1BCRMAP3K14 | |
| SCHEMBL17856228 | 0.91 | MAPK1 (0.83) | MAPK1MAPK3MAP3K14MAPK6 | |
| SCHEMBL17837246 | 0.91 | MAPK1 (0.83) | MAPK1MAPK3MAPK6 | |
| SCHEMBL17837275 | 0.90 | MAPK1 (0.81) | MAPK1MAPK3MAP3K14MAPK6 | |
| SCHEMBL17871041 | 0.90 | MAPK1 (0.81) | MAPK1MAPK3ABL1BCRMAP3K14 | |
| SCHEMBL17837241 | 0.90 | MAPK1 (0.81) | MAPK1MAPK3ABL1BCRMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090321-A1 | TREATMENT OF CANCER WITH A KRAS INHIBITOR | ALTEROME THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20250332160-A1 | COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF ERK INHIBITOR | KOREA INSTITUTE OF RADIOLOGICAL & MEDICAL SCIENCES (KR) | 2025-10-30 | — | — | US | claimed |
| EP-4629995-A1 | COMBINATION THERAPY FOR THE TREATMENT OF GLYOBLASTOMA | The University of Florida Research Foundation, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20250228826-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2025-07-17 | — | — | US | claimed |
| CN-119790069-A | Combinations of Gremlin-1 antagonists and inhibitors of Ras-Raf-MEK-ERK signaling | UCB生物制药有限责任公司 | 2025-04-08 | — | — | CN | claimed |
| WO-2025067459-A2 | THERAPIES FOR THE TREATMENT OF CANCER | D3 BIO (WUXI) CO., LTD. (CN) | 2025-04-03 | — | — | WO | claimed |
| EP-4523691-A1 | COMPOSITION CONTAINING ARIPIPRAZOLE AS ACTIVE INGREDIENT FOR ENHANCING ANTICANCER EFFECT OF ERK INHIBITOR | Korea Institute of Radiological & Medical Sciences (KR) | 2025-03-19 | — | — | EP | claimed |
| EP-4504777-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2025-02-12 | — | — | EP | claimed |
| WO-2025027223-A1 | DYRK2 INHIBITORS FOR TREATING TUMOURS WITH THE HYPERACTIVE MAPK/ERK PATHWAY | Universidad de Córdoba (ES) | 2025-02-06 | — | — | WO | claimed |
| WO-2020197917-A1 | SALTS OF 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROL-4-ONE COMPOUND AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-10-01 | — | — | WO | claimed |
| EP-3237423-B1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | LILLY CO ELI (US) | 2019-06-05 | — | — | EP | claimed |
| EP-3478292-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | Eli Lilly and Company (US) | 2019-05-08 | — | — | EP | claimed |
| WO-2018005234-A1 | COMBINATION OF ERK1/2 INHIBITOR COMPOUND WITH GEMCITABINE OR WITH GEMCITABINE AND NAB-PACLITAXEL FOR USE IN TREATMENT OF PANCREATIC CANCER | ELI LILLY AND COMPANY (US) | 2018-01-04 | — | — | WO | claimed |
| EP-3237423-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | Eli Lilly and Company (US) | 2017-11-01 | — | — | EP | claimed |
| US-20160375030-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-12-29 | — | — | US | claimed |
| US-9526733-B1 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-12-27 | — | — | US | claimed |
| US-9469652-B2 | ERK inhibitors | ELI LILLY AND COMPANY (US) | 2016-10-18 | — | — | US | claimed |
| WO-2016106029-A1 | THIENO[2,3-C]PYRROL-4-ONE DERIVATIVES AS ERK INHIBITORS | ELI LILLY AND COMPANY (US) | 2016-06-30 | — | — | WO | claimed |
| US-20160176896-A1 | ERK INHIBITORS | ELI LILLY AND COMPANY | 2016-06-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375030-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | MAPK1 2/4885MAPK3 3/4885ABL1 109/4885 |
| US-20160176896-A1 | ERK INHIBITORS | MAPK4, MAPK1, MAPK3 | MAPK1 2/4885MAPK3 3/4885ABL1 109/4885 |
| US-20250228826-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | KRAS, NRAS, BRAF | MAPK1 6/4885MAPK3 15/4885ABL1 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.